NR1H4 and primary biliary cholangitis: For example, we have shown [15] that treatment of a late stage mouse model of PBC (dominant-negative TGFb receptor II, dnTGFbRII at 32 wk of age) with Sct for 8 wk reduced hepatic total BA content and induced in female dnTGFbRII mice a significant reduction in taurine-conjugated b-muricholic acid, an antagonist of farnesoid X receptor, which after BA activation regulates bile acid synthesis, metabolism, and transport [63].